Evidence map›Paper›PMID 31686887›Full record

ArticleClinical, cosmetic and investigational dermatology2019

Assessment of macrophage migration inhibitory factor in patients with verruca vulgaris.

Neveen Emad Sorour, Ahmed Mohamed Hamed, Hala Abd-El Mageed Tabl, Amira Abd-El Aziz Ahmed

Open access · goldAbstract read
In one paragraph

Article in Clinical, cosmetic and investigational dermatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Neveen Emad SorourDepartment of Dermatology, Venereology and Andrology, Faculty of Medicine, Benha Univesity, Benha, Egypt.
Ahmed Mohamed HamedDepartment of Dermatology, Venereology and Andrology, Faculty of Medicine, Benha Univesity, Benha, Egypt.
Hala Abd-El Mageed TablDepartment of Medical Microbiology and Immunology, Faculty of Medicine, Benha Univesity, Benha, Egypt.
Amira Abd-El Aziz AhmedDepartment of Dermatology, Venereology and Andrology, Faculty of Medicine, Benha Univesity, Benha, Egypt.
Benha University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCommon warts are caused by human papillomaviruses (HPVs), they are among the most common cutaneous viral infections. Macrophage migration inhibitory factor (MIF) is an essential contributor in many inflammatory and immune skin diseases. Yet, its role in the pathology of common warts is unclear.

objectiveTo assess MIF levels in lesional and perilesional skin in patients with common warts in comparison to apparently healthy control group with matching age and sex. SUBJECTS AND

methodsA case-control study performed on 60 patients with common warts (group A) and 30 age and sex matching healthy controls (group B). Two biopsies were taken from each patient in group A; one from the lesion (lesional) and the other one from the skin around the wart (perilesional), while biopsies of controls were taken from matched sites to patients. Measurement of MIF in all groups was done by quantitative ELISA kits.

resultsSignificant high MIF levels were detected in lesional and perilesional skin biopsies compared to controls (

conclusionThe significantly elevated MIF levels in lesional and perilesional skin biopsies compared to controls point to its role in wart progression from HPV infected cells.

Indexed as

common wartshuman papillomavirusmacrophage migration inhibitory factor

Identifiers

PMID31686887
PMCPMC6709820
OpenAlexW2969634118

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.